↓ Skip to main content

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

Overview of attention for article published in Alzheimer's Research & Therapy, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
6 X users
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
212 Dimensions

Readers on

mendeley
329 Mendeley